CA-WIND-RIVER
3.5.2022 12:02:09 CEST | Business Wire | Press release
Wind River® , a global leader in delivering software for mission-critical intelligent systems, today announced that Hyundai Mobis, one of the world’s largest vehicle technology innovators and suppliers, and Hyundai AutoEver has signed an agreement to establish a strategic relationship that includes collaboration with Wind River Studio for the development of an automotive software framework and continuous test and test automation capabilities, as well as advanced software lifecycle management.
“As we move toward a more connected and autonomous future, software is at the center of enabling that reality,” said Avijit Sinha, chief product officer, Wind River. “Wind River Studio can help automotive leaders such as Hyundai Mobis and Hyundai AutoEver achieve a modernized development framework across cloud and edge, combined with software lifecycle management capability to enable them to accelerate their innovation and advance the software defined vehicle.”
“Hyundai Mobis plans to continue to introduce new services by adding future mobility technology to intelligent vehicles through extensive cooperation,” said Chang Jae-ho, senior vice president at Hyundai Mobis.
“Hyundai AutoEver plays the role of software specialist in the Hyundai Motor Group and is leading the team towards digital transformation to revolutionize software development and verification processes throughout vehicle development,” said Kim Seong-woon, vice president, head of the Software Quality Innovation Division at Hyundai AutoEver. “Through close cooperation with Wind River, we will strengthen the function and efficiency of Hyundai AutoEver’s software integrated development environment platform and virtual verification platform to contribute to innovation in vehicle software development by Hyundai Mobis and group companies.”
The auto industry is amid its most significant revolution in more than 100 years. Research from Forbes indicates that automotive leaders believe an intelligent systems approach is central to strategies that can deliver up to a 30% growth in revenue opportunities, and in five years’ time, many of the core requirements for intelligent systems in this industry will need to be in place.1
The collaboration will leverage each company’s specialties and experiences to develop a best-in-class software development infrastructure for next-generation connected automobiles. The companies will work closely on methodologies to accelerate the development and delivery of automotive systems, including enhanced continuous test capabilities and test automation in both simulated and real hardware-based environments and new customer test infrastructures making use of virtual device management.
The Hyundai AutoEver team will play a key role working with Wind River on a software integrated development environment platform and virtual verification platform.
Studio provides a cloud-native platform for the development, deployment, operations, and servicing of mission-critical intelligent systems. Studio delivers a full lifecycle management platform for intelligent systems at cloud scale. Studio enables development workflows that reduce development costs and accelerate capabilities for building, testing, and deploying on the edge.
More information about Wind River Studio is available at www.windriver.com/studio .
About Wind River
Wind River is a global leader in delivering software for mission-critical intelligent systems. For 40 years, the company has been an innovator and pioneer, powering billions of devices and systems that require the highest levels of security, safety, and reliability. Wind River software and expertise are accelerating digital transformation across industries, including automotive, aerospace, defense, industrial, medical, and telecommunications. The company offers a comprehensive portfolio supported by world-class professional services and support and a broad partner ecosystem. To learn more, visit Wind River at www.windriver.com .
About Hyundai MOBIS
Hyundai Mobis is the no.7 global automotive supplier, with annual sales of nearly $30 billion USD. The company was founded in 1977 and is headquartered in Seoul, Korea. Hyundai Mobis aims to become a lifelong technology partner for vehicles and people. The company has outstanding expertise in sensors, sensor fusion in ECUs and software development for safety control. The company’s products also include various components for electrification, brakes, chassis and suspension, steering, airbags, lighting, and automotive electronics.
About Hyundai AutoEver
Hyundai AutoEver, a mobility software provider that reliably, efficiently, and innovatively supports software and infrastructure across in-car and out-car areas, builds a mobility software platform to flexibly connect hardware and software, and is creating new value for the upcoming mobility ecosystem.
1 Forbes/Wind River, “Characteristics of Intelligent Systems,” 2021
Wind River is a trademark or registered trademark of Wind River Systems, Inc., and its affiliates. Other names may be the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005428/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom